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ABSTRACT 
 
The frontotemporal dementias are a clinically, neuroanatomically and pathologically diverse group of 
diseases that collectively constitute an important cause of younger onset dementia. Clinically, the 
frontotemporal dementias characteristically strike capacities that define us as individuals, presenting 
broadly as disorders of social behaviour or language. Neurobiologically, these diseases can be regarded 
as ‘molecular nexopathies’, a paradigm for selective targeting and destruction of brain networks by 
pathogenic proteins. Mutations in three major genes collectively account for a substantial proportion of 
behavioural presentations, with far-reaching implications for the lives of families but also potential 
opportunities for presymptomatic diagnosis and intervention. Predicting molecular pathology from 
clinical and radiological phenotypes remains challenging, however certain patterns have been identified 
and genetically mediated forms of frontotemporal dementia have spearheaded this enterprise. Here we 
present a clinical roadmap for diagnosis and assessment of the frontotemporal dementias, motivated by 
our emerging understanding of the mechanisms by which pathogenic protein effects at cellular level 
translate to abnormal neural network physiology and ultimately, complex clinical symptoms. We 
conclude by outlining principles of management and prospects for disease modification. 
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INTRODUCTION 
Frontotemporal dementia (FTD) is a clinically, neuroanatomically and pathologically heterogeneous 
group of neurodegenerative diseases that share a propensity to target the frontal and temporal lobes of 
the brain1. Although substantially less common than Alzheimer’s disease, the disorders that comprise 
the FTD spectrum have disproportionate clinical and neurobiological importance. From a clinical 
perspective, FTD usually presents as a disturbance of complex behaviour, affecting predominantly 
inter-personal conduct or language (primary progressive aphasia, PPA), often in middle life; it is the 
major young onset dementia besides Alzheimer’s disease, and takes a devastating toll on social and 
occupational functioning. Moreover, a substantial proportion of cases are genetically mediated, with 
implications for family counselling and presymptomatic diagnosis. From a neurobiological perspective, 
FTD illustrates the effects of pathogenic proteins in promoting selective disintegration of neural 
assemblies and has transformed our understanding of the molecular and network mechanisms of 
neurodegenerative disease.  
The FTD spectrum encompasses three canonical clinico-anatomical variant syndromes, classified 
according to their leading features1,2. Behavioural variant FTD (bvFTD), the commonest of the major 
FTD phenotypes, presents with progressive decline in emotional reactivity and interpersonal and 
executive skills, associated with a variable profile of fronto-temporal atrophy. Semantic variant primary 
progressive aphasia (svPPA) presents with loss of vocabulary and ultimately degrades semantic 
knowledge of sensory objects and nonverbal concepts as well as words; it is characteristically 
associated with focal atrophy chiefly affecting the left antero-mesial temporal lobe. Nonfluent-
agrammatic variant primary progressive aphasia (nfvPPA) presents with impaired motor speech 
production and/or sentence construction, associated with relatively focal, predominantly left anterior 
peri-Sylvian atrophy. As they evolve, these syndromes overlap extensively with each other and with 
syndromes of atypical parkinsonism (progressive supranuclear palsy, PSP and corticobasal 
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degeneration syndrome, CBS) and less frequently, motor neuron disease (MND). A third progressive 
aphasia syndrome, logopenic aphasia3, is typically (though by no means inevitably) a variant 
presentation of Alzheimer’s disease. 
While clinical presentations compatible with FTD have been described for well over a century, the first 
detailed clinical and neuropathological descriptions were made by Arnold Pick4,5. In the modern era, 
interest was rekindled by recognition of the syndromes of semantic dementia6 and slowly progressive 
aphasia without generalized dementia7. This led to the formulation of ‘frontal dementia’8,9, the original 
Lund-Manchester consensus criteria for clinical diagnosis10 and identification of the first causative 
gene mutation11. Subsequent progress has been meteoric, with updating of diagnostic criteria for the 
canonical syndromic variants of FTD12,13, delineation of all major genetic, neuropathological and 
neuroanatomical substrates14,15,16,17 and creation of multi-centre international collaborations dedicated 
to presymptomatic diagnosis and therapeutic trial design18. However, robust and sensitive biomarkers 
of disease course and molecular pathology and effective therapies remain elusive and are presently the 
focus of an intense international research effort. 
EPIDEMIOLOGY 
Limited data suggest that the overall population prevalence of FTD is around 11/100,000 and incidence 
1.6/100,00019 but these values rise sharply between the fifth and seventh decades and are likely to be 
underestimates (chiefly on account of misdiagnosis), particularly in older age groups. FTD accounts for 
around 40% of cases of young onset dementia coming to post mortem20; onset is most often in middle 
life, but ranges very widely between the third and ninth decades. It has been proposed that 
developmental dyslexia (as a marker of intrinsic language system vulnerability) may predispose to 
subsequent emergence of primary progressive aphasia21 and certain population-level genetic risk 
factors have been identified22; however, the factors that promote sporadic FTD remain essentially 
unknown and we still lack stratified epidemiological data for different ethnic and socio-economic 
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groups. 
DISEASE NEUROBIOLOGY 
Histopathology 
The common pathological mechanism underpinning FTD is intracellular deposition of abnormally 
aggregated proteins in neural tissue23. Accordingly, diseases in the FTD spectrum are ‘proteinopathies’ 
and can be classified according to the major constituents of the cellular inclusions present (Figure 1). 
Around half of cases coming to post mortem have abnormal deposition of transactive response DNA-
binding protein 43 (TDP-43), which is ubiquitously expressed and broadly implicated in neuronal 
development and synaptic function; these cases are variably associated with neuronal cyotoplasmic and 
intranuclear inclusions and dystrophic neurites23, and can be subclassified according to the morphology 
and laminar distribution of the cellular inclusions17. Around 40% of post mortem cases have abnormal 
accumulation of hyperphosphorylated microtubule-associated protein tau, which is likely to disrupt 
axonal transport and maintenance of neuronal integrity; these cases can be subclassfied 
immunohistochemically according to whether abnormally deposited tau contains predominantly three- 
or four-repeat microtubule binding domains. A small minority of cases have deposition of a family of 
fusion oncogene proteins, involved in DNA and RNA metabolism; rarely, none of these proteins is 
present. The mechanisms via which these pathogenic proteins give rise to neurodegeneration and cell 
death continue to be defined23. 
Molecular genetics 
A substantial proportion of the FTD spectrum comprises genetically mediated diseases; this proportion 
varies widely between clinical syndromes, the most heritable being bvFTD and the least heritable 
svPPA24. In bvFTD, an autosomal dominant familial inheritance pattern signifying a pathogenic 
mutation may be elicited in 10 – 20% of cases and some history suggesting affected family members in 
a higher proportion2,25,26.	Three major causal genes account for the large majority (>80%) of cases of 
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familial FTD, with wide geographical variation in relative frequency, likely attributable to founder 
effects. Abnormal expansion of a hexanucleotide repeat on the open reading frame on chromosome 9 
(C9orf72), the most recently identified major genetic factor, is the most common cause of genetic FTD 
(and MND) worldwide, accounting for some 25% of familial FTD and 5% of apparently sporadic 
FTD27. Mutations in the progranulin (GRN) gene mutations account for a similar proportion of familial 
FTD and 1-5% of apparently sporadic cases28. Mutations in the microtubule-associated protein tau 
(MAPT) gene also account for a substantial number of familial FTD cases though the proportion varies 
widely across series29,30,31.  Mutations in a range of other genes collectively account for a minority of 
cases of familial FTD and (along with C9orf72) are particularly relevant to the overlap FTD-MND 
spectrum23; of these, mutations in the TANK-binding kinase 1 (TBK1) gene may be numerically the 
most significant32. MAPT mutations are associated with abnormal phosphorylated tau deposition 
whereas TDP-43 pathology is found in association with most other mutations (Figure 1). 
There is much interest in identifying genetic associations that might act as risk factors or phenotypic 
modifiers for the wider burden of sporadic FTD. Genome-wide association surveys have identified a 
number of potentially relevant factors, of which the best characterised are variants in 
TMEM106B22,33,34.  
Predicting molecular pathology 
A grail of neurodegenerative disease research is to uncover the mechanisms whereby molecular 
pathologies give rise to complex phenotypes and conversely, to predict the underlying proteinopathy 
from phenotypic features. This issue has important implications for understanding disease 
neurobiology, for clinical diagnosis, and ultimately, for development and rational use of disease-
modifying therapies. A key paradigm across the neurodegenerative disease spectrum is the destruction 
of neural circuits and macroscopic networks by ‘prion-like’ spread of pathogenic proteins, informed by 
vitro and animal models23,35. While core clinical phenotypes of FTD have been compellingly linked to 
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intrinsic large-scale brain networks14, network and phenotypic signatures of particular proteinopathies 
are less well established. Certain correspondences have been derived from combined 
neuropathological, genetic, neuroimaging and neuropsychological studies16,36,37 (see Figure 1) and 
these have been endorsed by neuroanatomical measures of earliest change in genetically defined 
FTD18. This has led to the proposal that diseases in the FTD spectrum may constitute ‘molecular 
nexopathies’: specific conjunctions of pathogenic protein and neural circuit characteristics. This idea 
has received some support from computational modelling and human functional neuroimaging 
studies38,39. However, individual variation and convergence of phenotypes as disease evolves greatly 
complicate the picture. Moreover, the closeness of the correspondence varies between proteins and 
phenotypes: whereas (for example) TDP type C pathology is closely aligned with semantic dementia 
and 4-repeat tau pathology with PSP, bvFTD is associated with a variety of neuroanatomical patterns 
and proteinopathies. This may in part reflect the difficulty of deconstructing complex clinical 
phenotypes, motivating the search for physiological markers of neural circuit dysfunction that may 
underpin such phenotypes and at the same time, may more closely reflect underlying molecular 
pathology (see Box 1). 
CLINICAL DIAGNOSIS 
General considerations 
Accurate diagnosis of FTD syndromes is challenging: clinicians’ experience of these diseases is often 
limited, and presentations dominated by personality change or aphasia are readily misinterpreted as 
psychiatric illness, stroke or other conditions, especially in the earlier stages. On the other hand, ‘over-
interpretation’ of brain atrophy on neuroimaging sometimes leads to a spurious diagnosis of FTD. 
Interviewing an informant is essential to form an accurate picture of the illness, particularly as 
communication problems or lack of insight may vitiate the patient’s own account. A detailed 
neurological examination is required to identify associated extrapyramidal or motor neuron deficits that 
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frequently develop during the course of the disease. Neuroimaging, ideally with MRI and interpreted 
by an experienced observer, is essential to corroborate the bedside impression; and where available, 
neuropsychological assessment is very valuable, to quantify key deficits and their evolution over time 
(which may be decisive in clinically ambiguous cases) and also to capture associated cognitive deficits 
that help to define the phenotype.  
In light of the major role played by pathogenic genetic mutations in FTD, a searching family history is 
mandatory. This is particularly pertinent in bvFTD. Potentially relevant family history extends to 
‘psychiatric’ disorders and MND and it should be borne in mind that ‘dementia’ and ‘Alzheimer’s 
disease’ were used clinically as catch-all diagnoses until comparatively recently.  If parents are 
deceased, ages at death should be documented. A significant number of FTD cases with confirmed 
mutations lack a recognised family history: this may reflect misdiagnosis as well as censoring. 
We now highlight principles that we have found useful in identifying canonical FTD syndromes and 
differentiating these from other disorders. It is important to recognise, however, that FTD not 
uncommonly presents with fragmentary or mixed phenotypes, not conforming closely to the simplified 
scheme presented here. 
Behavioural variant FTD 
This syndrome is characterised by early, progressive decline in interpersonal and executive skills and 
loss of social and emotional awareness. Current diagnostic criteria12 foreground a number of domains 
of behavioural and personality change derived from the history, notably social disinhibition, apathy and 
abulia (loss of motivation and initiative), emotional blunting with loss of empathy, perseverative, 
stereotyped or compulsive verbal and motor routines (often involving hoarding, counting or tidying), 
hyeperorality and altered feeding behaviour with a tendency to gluttony and sweet tooth. The criteria 
further emphasise executive dysfunction with relative sparing of episodic memory and visuospatial 
functions on neuropsychological assessment; and rank the diagnosis as possible, probable or definite, 
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based on the availability of corroborative neuroimaging, genetic or histopathological information.  
These criteria have been instrumental in improving recognition and furthering research in FTD 
internationally but there are several caveats on their bedside application. bvFTD is a strikingly diverse 
syndrome, both clinically and neurobiologically. Behavioural symptoms are protean and typically shift 
over time; the syndrome commonly presents in fragmentary form, many patients perform well on 
formal neuropsychological testing of executive function and the most telling features (such as loss of 
inter-personal warmth) are particularly difficult to quantify in the clinic. Social infringements may 
mean the patient is first seen by psychiatric or forensic services40. On the other hand, it is increasingly 
recognised that deficits of episodic memory are not uncommon in bvFTD while executive dysfunction 
is not particularly helpful in discriminating FTD from Alzheimer’s disease41 and posterior parietal 
cortical dysfunction may be prominent in some scenarios (such as GRN mutations42). Arguably more 
than any other syndrome in cognitive neurology, early diagnosis of bvFTD relies on a finessed history 
from an informant who knows the patient well. However, even the history of progressive functional 
decline – generally considered a tenet of dementia diagnosis – may be difficult to establish: a 
substantial minority of patients have a ‘phenocopy syndrome’ in which neuroimaging is normal and 
objective evidence of deterioration is lacking despite often eloquent testimony from the spouse or other 
caregivers. The basis for this phenocopy syndrome is still not clear: for unknown reasons, it appears to 
be more common in older males, and some cases have been found to harbour a C9orf72 mutation43. 
Certain other clinical features that point to bvFTD are not emphasised in the current criteria2. These 
include impaired social cognition (inability to interpret other people’s mental states and feelings and 
loss of awareness of social mores) and in tandem with this, altered sense of humour with a preference 
for nasty or slapstick comedy44; lack of insight regarding the effects of the illness, leading to reckless or 
ill-advised financial and other decisions; altered (usually, reduced) libido and affection45; and altered 
sensitivity to sound, pain and temperature46,47. New preoccupations may shift away from the inter-
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personal toward more ‘abstract’ artistic or musical pursuits46,48. Psychotic features including delusions 
and hallucinations or prominent anxiety and other affective disturbances may develop, more commonly 
in association with C9orf72 mutations and MND36,49. Language impairment frequently emerges later in 
the course of bvFTD: this tends to manifest as anomia and semantic deficits, signaling convergence 
with the syndromic spectrum of progressive aphasia, particularly svPPA50. 
On examination, the quality of the patient’s interactions with the examiner and other people are often 
more telling than their performance on cognitive tests; clues may include lack of insight into the 
difficulties recounted on the informant’s history, rude remarks or loss of social boundaries, profound 
inertia or impassivity (loss of social facial reactivity), failure to read a spouse’s emotions, 
distractibility, impulsivity, perseveration or environmental dependency (spontaneous handling of 
objects in the vicinity). Although the general neurological examination at presentation is often normal, 
many patients will develop parkinsonism (merging with the CBS - PSP spectrum) or MND features. 
Primitive reflexes and ‘frontal release signs’ tend to emerge late and are not particularly helpful 
diagnostically.  
Brain MRI at presentation generally shows a degree of frontal and/or temporal lobe atrophy, but this 
varies widely in severity and regional distribution, within and between the cerebral hemispheres, and is 
importantly modulated by the underlying molecular pathology (Figure 1). This variability maps onto 
separable clinico-anatomical sub-syndromes of bvFTD16,51, albeit with extensive overlap in individual 
patients. Among these, the syndrome associated with focal right temporal lobe atrophy is especially 
striking, with profound loss of emotional reactivity and awareness, topographical difficulties and 
sometimes unusual phenomena such as hyperreligiosity, hallucinations and cross-modal sensory 
experiences52; inability to recognise familiar faces (prosopagnosia) may be a leading feature, as part of 
a more general failure of social signal processing which also extends to abnormal physiological 
responses53, and as the syndrome evolves it overlaps increasingly with svPPA. Where MRI in bvFTD is 
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initially inconclusive, serial MRI studies at a yearly interval may document progressive brain atrophy 
and corroborate a clinical impression of deterioration. Functional neuroimaging (for example, FDG-
PET) has a limited role in diagnosis though may occasionally reveal regional hypometabolism where 
structural brain MRI is inconclusive. 
Semantic variant primary progressive aphasia 
The hallmark of this syndrome – also known as semantic dementia – is progressive breakdown of 
semantic memory: the memory system that mediates our cumulative knowledge of words, objects and 
concepts (in contrast, episodic memory - the store of autobiographical events – is particularly targeted 
by Alzheimer’s disease). Typically, svPPA presents as loss of vocabulary: there is characteristically a 
history of ‘forgetting the names’ of items, asking the meaning of familiar spoken or written words, and 
when reading aloud, a tendency to regularise words according to their surface orthography (‘surface’ 
dyslexia or dysgraphia; for example, sounding or spelling ‘sew’ as ‘soo’). The patient’s speech is, at 
least initially, easily passed as normal; it is fluent (even garrulous) and well-structured. However, 
mounting reliance on circumlocutions and imprecise approximations (e.g., ‘sparrow’ becomes ‘bird’ 
and ultimately ‘animal’ or ‘thing’) renders conversation increasingly empty of substance. Evolving 
nonverbal semantic impairment leads to prosopagnosia, visual and other sensory agnosias. A 
behavioural syndrome overlapping with bvFTD generally supervenes; obsessions centred on time with 
clock-watching and puzzles such as jigsaws and Sudoku are often particularly striking3, hyperacusis, 
tinnitus and abnormal sensitivity to bodily sensations (manifesting as somatic symptoms46,47,54,55) are 
common and impoverished self-and future-concepts may lead to nihilism and suicidality56,57. 
Perceptual, praxic, arithmetical and navigational skills are generally well preserved. 
On examination, anomia is generally marked but (because impaired naming or word retrieval occurs in 
a variety of settings) diagnosis rests on demonstrating impaired comprehension of single words (for 
example, by asking the patient to define or point to pictured items nominated by the examiner)3. Speech 
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is grammatical with normal articulation and prosody, and verbal working memory (indexed by 
repetition of polysyllabic words and phrases), visuospatial and other parieto-occipital cortical functions 
are intact. The general neurological examination is usually unremarkable at presentation though 
extrapyramidal and corticospinal signs may emerge later in the illness58,59. 
This clinical phenotype of svPPA is associated with a hallmark MRI signature of focal, asymmetric 
cerebral atrophy predominantly affecting the antero-medial and inferior temporal lobes, usually more 
marked on the left (Figure 1). There is stark involvement of temporal pole (which typically shows a 
‘knife-blade’ appearance due to marked gyral destruction), amygdala, anterior hippocampus and 
fusiform gyrus. So consistent is this profile (in contrast to the rather variable MRI profiles of other FTD 
syndromes) that the diagnosis should be questioned if it is absent. Typical svPPA is generally 
sporadic2,3, though we have seen it mimicked occasionally by MAPT, C9orf72 or TBK1 mutations.  
Nonfluent – agrammatic variant primary progressive aphasia 
This syndrome principally affects speech production and presents with effortful, hesitant, poorly 
constructed speech. It is more likely than other FTD syndromes to present in later life19. There is often 
a history of mispronouncing longer words and sometimes reappearance of a childhood stutter. Speech 
errors are frequent: with variable prominence, these affect individual speech sounds (manifesting as 
defective syllable selection - phonological errors - or articulation - phonetic errors), whole words 
(manifesting as defective selection between alternative responses, such as confusion of ‘Yes/ No’, 
‘his/her’ – ‘binary reversals’60 and sentences (grammatical errors). Articulatory difficulty or ‘speech 
apraxia’ often dominates the presentation and in pure form has been proposed to constitute a distinct 
sub-syndrome61, though other language deficits frequently emerge over time. As the illness unfolds, 
grammatical and spelling errors generally appear in the patient’s written output and comprehension of 
more complex messages is reduced, reflect deficits of receptive grammar or central auditory 
processing3,62,63. Many patients develop parkinsonism and features of the CBS – PSP spectrum (or less 
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commonly, MND) and swallowing often becomes affected. Executive dysfunction, apathy and 
depression (reflecting retained insight) are also frequent issues25, though many patients have 
remarkably preserved general intellect. 
On examination, there is generally obvious dysfluency; speech is marred by sound errors and may have 
a telegraphic quality due to omission of connecting words, though agrammatism is more reliably 
assessed from written sentence production. More subtle motor speech impairment can be brought out 
by asking the patient to repeat a sequence of syllables (such as ‘puh – ta – kuh’), which taxes 
articulatory agility. Repetition of polysyllabic words and phrases is comparably affected. There is often 
associated apraxia of posed orofacial movements such as yawning or whistling. Dominant parietal 
signs such as dyslexia (predominantly affecting the sounding of non-words such as proper names that 
rely on phonological decoding rather than vocabulary), limb apraxia and verbal working memory 
impairment and extrapyramidal signs such as supranuclear gaze palsy, limb rigidity, dystonia and 
postural instability frequently develop3,25,64, signifying spread of disease within peri-Sylvian cortical 
and cortico-subcortical networks. Patients with underlying CBS – PSP pathology tend to have reduced 
spontaneous language output disproportionate to the degree of motor speech impairment, and this 
‘dynamic aphasia’ may sometimes lead the presentation3,65,66. 
Brain MRI characteristically shows asymmetric atrophy of inferior frontal gyrus, insula and anterior 
superior temporal gyrus, more marked on the left (Figure 1); however, individual patients show atrophy 
profiles that vary widely in severity and posterior cortical extension. In ambiguous cases, serial MRI to 
assess progressive regional atrophy is often helpful. There may be associated atrophy of the midbrain 
and other subcortical structures67. While nfvPPA is substantially less likely to be genetically mediated 
than bvFTD, causative mutations are well documented2 and should be suspected where there is a 
relevant family history, suggestive MRI profile (Figure 1) or ‘complex’ mixed aphasic syndrome 
(associated, in particular, with GRN mutations3,62,68).  
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Differential diagnosis 
The key diagnostic priorities in a patient presenting with a syndrome compatible with FTD are to 
identify treatable or reversible processes that simulate FTD; and within the FTD spectrum, to identify 
genetic processes that may have implications for counselling or screening other family members. The 
distinction from primary psychiatric illness is relevant to all FTD syndromes, particularly in bvFTD 
and where psychotic features are present: this is generally resolved by neuroimaging but requires an 
initial index of suspicion, especially when a neuropsychiatric syndrome develops de novo in later life 
or with unusual features (such as abnormal eating behavior or faux pas). Language disorders can 
present with rather counter-intuitive symptoms, whereas isolated non-organic speech disorders are rare; 
an expert second opinion may be worthwhile.  
A fronto-subcortical cognitive syndrome with variably prominent executive and attentional 
compromise, neuropsychiatric changes and cognitive slowing is the final common pathway of many 
brain diseases, including potentially remediable surgical and inflammatory processes. In older people, 
cerebrovascular disease and (less commonly) dementia with Lewy bodies can closely simulate bvFTD, 
while in young adults, rare metabolic and genetic illnesses expand the differential diagnosis69,70. 
Neuroimaging in conjunction with a careful history and examination will often distinguish these 
diseases from the primary FTD spectrum. Identifying patients with probable underlying Alzheimer 
pathology is important in prognosis and future planning but also consideration of symptomatic therapy 
with acetylcholinesterase inhibitors. In the spectrum of language presentations, Alzheimer’s disease is 
most reliably signaled by logopenic aphasia, which presents with anomia and word finding pauses 
without the profound semantic impairment of svPPA or the articulatory and agrammatic errors of 
nfvPPA but with disproportionate difficulty repeating phrases and sentences versus single words, 
reflecting a core deficit of verbal working memory linked to involvement of dominant temporo-parietal 
cortex3. More problematic is the ‘frontal variant’ of Alzheimer’s, presenting with prominent executive 
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or behavioural changes71; this can be particularly difficult to distinguish clinically from FTD in the 
individual case, underlining the value of CSF examination or amyloid-PET neuroimaging to identify 
Alzheimer biomarkers, especially in younger patients.  
A ‘diagnostic mandala’ for FTD emphasising key differentiating clinical, neuroimaging and laboratory 
features of major phenotypes and underlying pathologies is summarised in Figure 2. 
OUTLOOK AND MANAGEMENT 
General considerations 
No treatments have currently been shown to alter the underlying disease process in any FTD syndrome. 
The prognosis in FTD is therefore one of steadily increasing disability and ongoing decline to 
dependency. However, life expectancy varies widely across the FTD spectrum19,72, ranging from a few 
years in FTD – MND to over a decade in some patients with bvFTD and svPPA. As the disease 
evolves, syndromes tend to converge and non-cognitive neurological features often develop73. 
However, we currently lack reliable markers of disease severity, stage and prognosis to inform 
counselling of individual patients and families.   
Management of FTD begins with provision of accurate information about the nature of the illness to the 
patient, family members, caregivers and relevant health professionals. This is a truly life-changing 
diagnosis: erosion of the sufferer’s personal identity (‘living with a stranger’) can be profoundly 
distressing for those close to them. Understanding its impact on the patient’s social milieu, day-to-day 
functioning and care needs, together with appropriate safe-guarding and anticipating future loss of 
independence are integral to managing the illness successfully. There are a number of excellent on-line 
resources (for example: http://ecdc.org.au/ftd-toolkit.htm) and access to a local or national lay support 
group oriented to FTD (http://www.raredementiasupport.org/groups/) can be a transformative source of 
practical advice and informal counselling. Practical and emotional support and regular respite for 
caregivers are integral to successful management but easily overlooked.  
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Table 1 presents a problem-based management ‘checklist’ under the broad themes of optimising quality 
of life, controlling symptoms, supporting caregivers and planning for the future. Given the current 
dearth of adequate clinical trials, management recommendations in FTD are based largely on clinical 
experience and anecdote.  
Non-pharmacological strategies 
In general, for control of symptoms non-pharmacological strategies are preferable to medications, 
which are difficult to use rationally, of limited efficacy and prone to produce unwelcome side effects in 
people with FTD. This in turn requires engagement of local multidisciplinary support services, such as 
speech and language and occupational therapy, audiology, clinical psychology and social work, ideally 
coordinated by the general practitioner and/or local community mental health team. Caregivers may 
need to be educated and empowered to take an active management role. Patients benefit from a stable 
and structured environment tailored to their particular capacities and interests; safe-guarding is 
essential, encompassing (for example) activities linked to occupation, hobbies, responsibility for 
children or elderly dependents, financial decision making and driving. The last is often particularly 
challenging where manual competence is retained but judgment and insight are compromised. 
Communication is an important issue across syndromes and disease stages, particularly in the 
progressive aphasias. While the place of specific language retraining programmes and electronic 
devices remains undefined3, there is unquestionable value in simple communication aids such as cards, 
picture books and medical alert bracelets. As the disease evolves, the focus of management shifts from 
maintaining independence to controlling aggression and other challenging behaviours and addressing 
neurological disability due to declining mobility, impaired swallowing and nutrition and disturbed 
homeostatic and autonomic functions. It is important that general medical health needs are not 
overlooked in the face of anosognosia or altered awareness of pain and other bodily signals. 
Pharmacotherapy 
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There is a place for pharmacotherapy in FTD where non-pharmacological strategies are ineffective. 
Use of acetylcholinesterase inhibitors and memantine is worthwhile in patients with biomarker 
evidence of Alzheimer’s pathology but evidence of benefit in other cases of FTD is not secure and 
some patients may experience an escalation of behavioural disturbance74,75. As serotonergic function is 
reduced in FTD76, use of serotonergic modulators is more apposite a priori and modest behavioural 
benefit has been shown for trazodone and citalopram though not paroxetine77,78,79. Neuroleptic 
medication may be required to manage psychosis, intractable aggression or intrusive compulsions 
though care is needed, as patients with FTD are at risk of significant extrapyramidal side effects, even 
with newer generation agents80,81; in this situation we favour low-dose risperidone or quetiapine, with 
close clinical monitoring. 
Genetic testing and the family 
The issue of genetic testing in FTD is a complex one for which clear guidelines are currently lacking. 
The case is most straightforward where there is a family history of FTD, young onset dementia, major 
psychiatric disorder or MND, particularly with the suggestion of autosomal dominant inheritance. We 
have a low threshold for screening genetic mutations in any patient with FTD (in particular, bvFTD) 
where the findings would be potentially important for other family members (for example, adult 
children planning their own families) and the family should be involved in the decision to do an initial 
diagnostic test. If a causative mutation is found, it is often helpful to meet with at-risk family members 
separately to talk through the nature of the illness and specific implications relevant to them. As with 
any genetic illness, those who would like to take matters further should be referred for counselling with 
an experienced geneticist prior to deciding whether to have a presymptomatic test. Although general 
correlations can be identified at population level82, it is not possible currently to offer reliable and 
specific advice regarding likely age at onset or indeed, initial symptoms, should a pathogenic mutation 
be identified presymptomatically. 
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FUTURE PROSPECTS 
The field of FTD research and practice is poised at an exciting juncture. Future progress will depend on 
translating recent unprecedented advances in pathobiology to improved methods of diagnosis, disease 
tracking and ultimately, disease-modifying therapies.  
The finding that molecularly-determined structural changes in major genetic forms of FTD precede the 
onset of clinical symptoms by many years was an important milestone suggesting that presymptomatic 
disease detection and intervention is feasible, at least in principle18. Furthermore, this was only made 
possible by the creation of a multi-centre international collaboration (the Genetic Frontotemporal 
Dementia Initiative, GenFI), allowing data from families with rare mutations to be acquired, pooled 
and analysed on a common platform. GenFI and the US-based Longitudinal Evaluation of Familial 
Frontotemporal Dementia and Advancing Research and Treatment for Frontotemporal Lobar 
Degeneration projects83 are equipped to drive large-scale clinical trials of disease-modifying therapies 
covering the FTD spectrum, as these become available, from the earliest stages of disease. To date, 
studies of FTD trial methodology and sample size estimates have focused on structural MRI84: 
essentially, a measure of cell death (brain atrophy). This is a blunt tool with which to assess disease and 
treatment effects. Ideally, sensitive and dynamic biomarkers are required that provide a ‘read-out’ of 
cellular and synaptic function, to identify the culprit protein and its physiological impact before 
irrecoverable neural damage occurs and to determine rapidly if candidate treatments are working. The 
heterogeneity of FTD means that biomarker development is a more challenging proposition in this 
group of diseases than in (for example) Alzheimer’s disease. However, there is currently considerable 
interest in identifying genetic risk factors and modifiers in sporadic FTD from genome-wide 
association studies33, new tools such as molecular ligand neuroimaging that can capture deposition of 
protein tau in vivo85 and wet biomarkers derived from CSF and blood assays of proteins such as tau and 
its metabolites, neurofilament light chain, TREM2 and progranulin86-90: these approaches may detect 
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and track neuronal injury and dysfunction more closely than has previously been possible. In addition, 
there is growing awareness of the systemic metabolic and physiological correlates of deranged 
homeostatic processing in FTD91,92. Complementary tools derived from functional neuroimaging, 
autonomic and electrophysiology39,53,88,93 address neural network dysfunction and may yield proxies of 
complex clinical phenotypes that are difficult to measure directly. Multimodal biomarkers combining 
these different measures may provide the most sensitive and specific pathophysiological indices of 
underlying pathogenic protein activity88,94. 
A number of promising candidate approaches to disease modifying therapy are now entering trials. 
Individuals with known genetic mutations or highly predictable, sporadic pathology based on clinical 
phenotype (such as tauopathy in progressive supranuclear palsy) form the logical initial target groups. 
Such work has a crucial preclinical phase via drug discovery and development of therapeutic 
approaches in vitro and animal models, including pluripotent stem cells derived from patients with 
defined diseases and transgenic mice that can be used to generate model neuronal systems95,96,97. 
Proposed disease-modification strategies have included anti-tau antibodies and microtubule 
stabilisation, stimulation of progranulin expression and release, modulation of autoimmunity and 
neuroinflammation (particularly relevant to GRN mutations) and, most dramatically (informed by 
recent progress in Huntington’s disease), silencing of toxic C9orf72 RNA messengers using anti-sense 
oligonucleotides83,98. To date, the value and feasibility of these strategies remain unproven in FTD. 
Alongside disease modification, there is a need to develop rational and effective, pathophysiologically 
informed interventions for harnessing residual capacities99 and controlling symptoms: recent examples 
include the use of intranasal oxytocin for redressing emotional indifference in FTD syndromes100 and 
cognitive rehabilitation and transcranial stimulation techniques in the progressive aphasias101,102. Such 
interventions are likely to become even more relevant as effective disease modifying therapies become 
available.  
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Box 1.   Deconstructing C9orf72-associated frontotemporal dementia  
The clinical phenotype of C9orf72 mutations (the most common genetic cause of FTD) is complex but 
neuropsychiatric features, including anxiety and somatically focussed delusions and misperceptions, 
are often prominent36,49. Neuropathologically, these cases have deposition of pathogenic proteins TDP-
43 and p62 targeting a distributed cortico-subcortical network including cerebellum, thalamus, insula 
and parietal lobe: this network has been shown to be affected early in the evolution of disease, many 
years prior to onset of typical clinical symptoms18,36 and its involvement correlates with the presence of 
neuropsychiatric symptoms49. In the healthy brain, this network mediates body schema processing, 
while derangements of body schema have been shown to produce schizotypal features similar to those 
observed in C9orf72 mutation carriers103: and indeed, psychophysiological abnormalities of body 
schema processing (tactile discrimination, self-nonself differentiation, pain and temperature 
homeostasis) have been shown to differentiate C9orf72 mutation carriers from other forms of FTD47,104. 
Taken together, these findings unite a molecular pathological signature with a complex behavioural 
phenotype, via a physiological mechanism instantiated in specific brain network disintegration. 
C9orf72-associated FTD could be considered a ‘molecular nexopathy’: a coherent conjunction of 
pathogenic protein, neural network and clinical phenotype35. Deconstruction of other complex 
phenotypes within the FTD spectrum and identification of specific physiological markers may allow 
analogous linkages to be established for a range of pathogenic proteins; abnormal physiological coding 
of internal and externally generated emotional signals is richly differentiated across the FTD 
spectrum53,55,93,105 and may yield quantifiable proxies of socio-emotional behavioural disturbances that 
are difficult to measure directly. 
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Table 1. A problem-oriented management ‘checklist’ for frontotemporal dementia 
Problem Possible strategies 
Optimising quality of life  
Employment Occupational health assessments; vocational counselling, redeployment 
and rehabilitation; medical retirement 
Finances Expert financial advice; review banking arrangements; assessment of 
eligibility for allowances, disability support 
Safe-guarding Identify and assess any physical / emotional / socio-economic / forensic 
risks to patient or potentially vulnerable contacts (children, elderly); 
engage family, other caregivers, social services as appropriate 
Driving Inform licensing authority and insurer (legal frameworks); assess current 
safety and competence from caregiver report; assess relevant skills 
(judgement and impulse control, praxis, motor, visuospatial); practical 
driving test in borderline cases; limit access to motor vehicles if required 
Home environment Occupational therapy assessment of potential hazards (e.g., falls risk), 
barriers to mobility; home modifications (e.g., rails, safety locks) 
Controlling symptoms  
Impaired communication Speech and language therapy; communication aids and devices; alert 
card or bracelet 
Disinhibition, impulsivity, 
wandering 
Environmental modification; supervision; avoid triggers; programmed 
activities (ensure adequate mental stimulation); limit setting and 
redirection; tracking devices 
Apathy, lack of initiative / 
empathy 
Reinterpretation (for caregivers); routines; engage retained interests 
(e.g., puzzles, music); assess mood / impact on care; exclude intercurrent 
comorbidity 
Depression, anxiety Psychological support and counselling; consider SSRI 
Agitation, aggression Avoid triggers; reassurance; displacement activities; exclude intercurrent 
comorbidity; consider SSRI, new generation neuroleptic  
Delusions, hallucinations Consider new generation neuroleptic if distressing / disruptive 
Abnormal eating behaviour, Dietary, dental and swallowing assessments; monitor weight; control 
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dysphagia access to food and/or alcohol; discussion of assisted feeding where 
appropriate; consider SSRI (hyperphagia) 
Hypersexuality*, other 
compulsions 
Avoid triggers; limit setting and redirection; substitute activities; 
consider SSRI 
Sleep disturbance Sleep routines and ‘hygiene’; avoid evening caffeine / alcohol, daytime 
naps; regular exercise; consider sleep study to exclude nocturnal 
seizures, sleep apnoea, parasomnia; review medication list; consider 
SSRI with sedative potential (e.g., mirtazapine), melatonin 
Abnormal pain, temperature 
perception 
Care with medical assessments, interpretation of symptoms (avoid 
under- / over-investigation) 
Motor disability Environmental modification; mobility aids; physiotherapy; review 
medication list; consider trial of levodopa / dopamine agonist 
Bladder and bowel 
dysfunction 
Environmental modification (cues / assistance with toileting, access to 
toilet); continence / urological assessment (address prostatism, other 
intercurrent factors); exclude infection; address constipation; pads, 
diapers; new generation medications for bladder overactivity where 
indicated 
Intercurrent comorbidities Assess and correct visual, hearing deficits; optimisation of reversible 
vascular risk factors; age-appropriate health screens; liaise with surgical 
and other specialties as indicated 
Supporting caregivers and 
families 
 
Loss of income Carer allowance 
Loss of social networks  Contact regional / national support groups 
Emotional distress Education and reinterpretation of behaviours; counselling (couple / 
individual / bereavement) and assess carer’s mental health if indicated 
Care burden Periodically reassess level of care required, adequacy of provision (e.g., 
night-time); day centres and related programmed activities; external / 
social care; community nurses and health visitors; assist decision-
making re residential care 
Caregiver burnout Arrange programmed respite; empower asking for help; engage available 
social networks; formal psychological therapy for carers 
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Special needs  Involve school and child counsellors for younger children; assess impact 
if patient has been acting as a carer 
Future planning  
Decision-making: financial, 
testamentary, medical 
Arrangements for power of attorney, will; assessment of capacity 
(should be dynamic and specific) 
Living arrangements Future-proofing of home set-up and local area; access to services; scope 
day centres and residential care options; inform local shopkeepers, 
police 
Medical care arrangements Engage local GP (ideally, ensure continuity), community mental health 
team and/or neurologist; palliative care services as appropriate 
End-of-life care Advance decisions, living will 
Genetic implications for 
family 
Personalised discussion with family members; referral to clinical 
geneticist for discussion of pre-symptomatic genetic screening 
 
This table summarises some key themes and common problems in the management of patients with 
frontotemporal dementia, together with management strategies that we have found to be useful in our 
clinical practice. A number of problems are relevant across frontotemporal dementia syndromes, 
though issues around conduct and socio-emotional awareness tend to be more significant earlier in 
behavioural variant frontotemporal dementia and communication problems more salient in the 
progressive aphasias. SSRI, selective serotonin reuptake inhibitor (e.g. citalopram, trazodone); *most 
patients have reduced libido 
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Figure 1.  The histopathological, genetic, neuroanatomical and clinical spectrum of frontotemporal dementia. Abnormal accumulation 
of transactive response DNA-binding protein 43 (TDP-43) or hyperphosphorylated tau (oblongs, bottom) account for most cases of FTD; 
these proteinopathies are further subclassified on morphological or immunohistochemical grounds into TDP types A, B, C and D and tau 
principally containing three-repeat (3R, classical Pick’s disease) or four-repeat (4R) microtubule binding domains. A minority of FTD cases 
have a proteinopathy in the FET (fused in sarcoma (FUS), Ewing’s sarcoma, TATA-binding protein-associated factor 15) spectrum or 
rarely, lack pathological accumulation of any of these proteins.  Mutations of three major genes (ellipses, bottom) account for a substantial 
proportion of TDP-43 (progranulin gene, GRN; chromosome 9 open reading frame 72, C9orf72)) and tau (microtubule-associated protein 
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tau gene, MAPT) cases. Mutations of a number of other genes can also cause FTD, including rare cases with mutations of the valosin-
containing protein gene (VCP) and TDP type D pathology. Vertical columns indicate the correspondence between molecular pathology 
(bottom), neuroanatomy (brain MRI, middle panels) and clinical features (filled oblongs, top), which varies across the FTD spectrum (see 
text). T1-weighted coronal MRI sections (presented with the left cerebral hemisphere on the right) show regional atrophy profiles produced 
by particular molecular pathologies, including the following characteristic associations: a, strikingly asymmetric atrophy of cerebral 
hemispheres with GRN mutation, c, asymmetric, predominantly antero-mesial temporal lobe atrophy with TDP type C; e, asymmetric 
atrophy with classical Pick’s disease; f, relatively symmetric, predominantly antero-mesial temporal lobe atrophy with MAPT mutation; h, 
disproportionately severe caudate atrophy with FUS. Regional atrophy profiles with C9orf72 mutations (b), VCP mutations (d), Pick’s 
disease (e) and corticobasal degeneration (g) are variable (d illustrates that atrophy can be minimal even with proven FTD pathology). 
Clinically, behavioural variant (bv)FTD can be produced by any pathology and has a variety of MRI associations (compare a, b, d, f, h); 
nonfluent – agrammatic variant (nfv) PPA is more frequently (but not exclusively) underpinned by tau pathology and associated with 
predominantly left anterior peri-Sylvian atrophy of variable severity (e, g), while semantic variant (sv) PPA is most often underpinned by 
TDP type C pathology and has a highly consistent MRI profile (c). Intersecting these canonical FTD syndromes, certain pathologies are 
associated with particular constellations of clinical features (unfilled oblongs, top),  notably: TDP type B pathology with motor neuron 
disease (MND); TDP type C pathology with semantic dementia (SD; svPPA plus nonverbal semantic impairment); VCP mutations with 
inclusion body myopathy, Paget’s disease of bone and frontal dementia (IBMPFD); and 4R tau pathology with atypical parkinsonism 
(park), corticobasal and progressive supranuclear palsy syndromes (CBS – PSP). Figure 2 presents a diagnostic synthesis of these various 
associations. 
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Figure 2.  A ‘diagnostic mandala’ for frontotemporal dementias. Certain combinations of clinical 
features (central grey circles) and investigation findings (white circle) most usefully define phenotypes 
and predict particular molecular pathologies in the FTD spectrum (colour coded on outer circle; see 
also Figure 1). Core behavioural (B) and language (L) presentations correspond to the major variant 
syndromes of bvFTD and PPA; aphasic presentations can be subclassified into the major PPA variants 
according to whether the key clinical feature is impaired speech production (speech apraxia, sp 
apraxia or agrammatism, agram; nfvPPA), impaired single word comprehension (comp words; 
svPPA) or impaired repetition of phrases but relatively intact repetition of single words (rep phrase; 
logopenic aphasia) (see text). A history of similarly affected family members (fam), particularly an 
autosomal dominant inheritance pattern, is an important clue to a causative genetic mutation. Among 
these, clinical features of motor neuron disease (MND) predict a C9orf72 mutation (TDP-B pathology) 
and the rare constellation of inclusion body myopathy (IBM) and Paget’s disease of bone (PB) predicts 
a VCP mutation; while on MRI, strongly asymmetric atrophy predominantly affecting one cerebral 
hemisphere with parietal extension (asym hem) predicts a GRN mutation (TDP-A pathology) and 
relatively symmetric, focal anterior temporal lobe atrophy (sym TL) predicts a MAPT mutation (see 
Figure 1). These patterns warrant genetic screening with appropriate family counselling. Among 
diseases that are usually sporadic, atypical parkinsonism with features of corticobasal syndrome, 
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postural instability or supranuclear gaze palsy (atyp park) tends to predict a tauopathy such as 
corticobasal degeneration (CBD) or progressive supranuclear palsy (PSP); svPPA with strongly 
asymmetric focal anterior temporal lobe atrophy (asym TL)  on MRI predicts TDP type C (TDPC) 
pathology; aggressive disease with young onset (young aggr) and severe caudate atrophy (caud) on 
MRI is characteristic of FUS pathology; while classical Pick’s disease may present with bvFTD, 
nfvPPA or atypical PPA associated with asymmetric atrophy (asym) of variable distribution on MRI. 
Logopenic aphasia or (less commonly) bvFTD associated with positive Alzheimer’s disease 
biomarkers (pos AD biomarkers; raised CSF total tau:beta-amyloid1-42 ratio or positive amyloid-PET 
scan) predict underlying Alzheimer’s pathology; while some patients will have other pathologies 
outside the primary FTD spectrum (not FTD), generally signalled by clinical and/or MRI features 
atypical for FTD. 
